Effects of radiotherapy on lymphocytes in patients with middle and lower esophageal cancer and its relationship with prognosis

Table 1 Clinical baseline characteristics of 112 patients with esophageal squamous cell carcinoma, n (%)

Characteristics	All patients, n = 112	G1-G3 ALC nadir, n = 80	G4 ALC nadir, n = 32	P value
Gender				0.041
Male	83 (74.1)	55 (68.8)	28 (87.5)
Female	29 (25.9)	25 (31.3)	4 (12.5)
Age, years				0.064
≤ 67	58 (51.8)	37 (46.3)	21 (65.6)
> 67	54 (48.2)	43 (53.8)	11 (34.4)
BMI				0.501
< 24 kg/m2	68 (60.7)	47 (58.8)	21 (65.6)
≥ 24	44 (39.3)	33 (41.3)	11 (34.4)
Tumor length (cm)				0.509
≤ 5	51 (45.5)	38 (47.5)	13 (40.6)
> 5	61 (54.5)	42 (52.5)	19 (59.4)
T stage				0.509
T1 + T2	51 (45.5)	38 (47.5)	12 (37.5)
T3 + T4	61 (54.5)	42 (52.5)	20 (62.5)
N stage				0.017
N0	17 (15.2)	14 (17.5)	3 (9.4)
N1	67 (59.8)	52 (65.0)	15 (46.9)
N2	28 (25.0)	14 (17.5)	14 (43.8)
Clinical stage				0.003
I + II	73 (65.2)	59 (73.8)	14 (43.8)
III	39 (34.8)	21 (26.3)	18 (56.3)
RT dose				0.336
≤ 60 Gy	62 (55.4)	42 (52.5)	20 (62.5)
> 60 Gy	50 (44.6)	38 (47.5)	12 (37.5)
Treatment regimen				0.244
RT alone	41 (36.6)	33 (41.3)	8 (25.0)
Sequential CRT	27 (24.1)	17 (21.3)	10 (31.3)
Concurrent CRT	44 (39.3)	30 (37.5)	14 (43.8)
RT technique				0.321
ENI	41 (36.6)	27 (33.8)	14 (43.8)
IFI	71 (63.4)	53 (66.3)	18 (56.3)

ALC: Absolute lymphocyte count; BMI: Body mass index; RT: Radiotherapy; CRT: Chemoradiotherapy; ENI: Elective nodal irradiation; IFI: Involved-field irradiation.